

Phase I Trial: Quotient Code QSC303820

Submission date 03/04/2026	Recruitment status Recruiting	☒ Prospectively registered ☐ Protocol
Registration date 27/04/2026	Overall study status Deferred	☐ Statistical analysis plan ☐ Results
Last Edited 11/05/2026	Condition category Other	☐ Individual participant data ☒ Record updated in last year

Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Public, Scientific

Contact name

None Kirsty Webster

Contact details

Quotient Sciences Limited
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)3303031000
recruitment@weneedyou.co.uk

Type(s)

Principal investigator

Contact name

Dr David Everton

Contact details

Quotient Sciences Limited
Mere Way
Ruddington Fields

Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)3303031000
recruitment@weneedyou.co.uk

Additional identifiers

Integrated Research Application System (IRAS)
1013137

CRO Study Code
QSC303820

Study information

Scientific Title

Phase I Trial: Quotient Code QSC303820 [the full scientific title will be published within 30 months after the end of the trial]

Study objectives

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 08/05/2026, London - Brent Research Ethics Committee (Health Research Authority 2 Redman Place Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 7104 8117; brent.rec@hra.nhs.uk), ref: 26/LO/0165

Primary study design

Interventional

Allocation

Non-randomized controlled trial

Masking

Open (masking not used)

Control

Active

Assignment

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Purpose

Phase I study in healthy volunteers

Study type(s)**Health condition(s) or problem(s) studied**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)**Completion date**

16/11/2026

Eligibility**Key inclusion criteria**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Healthy volunteers allowed

Yes

Age group

Adult

Lower age limit

18 Years

Upper age limit

55 Years

Sex

All

Total final enrolment

0

Key exclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

20/05/2026

Date of final enrolment

16/11/2026

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Quotient Sciences Limited

Mere Way

Ruddington Fields

Ruddington

Nottingham

England

NG11 6JS

Sponsor information

Organisation

Quotient Sciences Limited

Funder(s)

Funder type

Funder Name

Quotient Sciences Limited

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available